Stockreport

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update [Yahoo! Finance]

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100. Supportive data from preclinical study in atherosclero [Read more]